KPV

What it is

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). It inhibits pro-inflammatory cytokine production by acting on intracellular inflammatory pathways — specifically NF-κB signalling — independent of the melanocortin receptors that α-MSH itself targets. This means it reduces inflammation at the cellular level without the pigmentation side effects associated with melanocortin receptor activation.

Inflammatory signalling in the gut, skin, and connective tissue reduces. In gut-focused protocols, mucosal inflammation and barrier permeability improve. In skin protocols, inflammatory conditions such as dermatitis settle. The anti-inflammatory effect is broad — KPV does not target a single organ system but acts wherever inflammatory cytokine activity is elevated.

• Reduction of NF-κB activity and pro-inflammatory cytokine production in cell models
• Improved outcomes in colitis animal models — mucosal healing and inflammation reduction
• Anti-inflammatory action in skin wound healing models
• Protective effects on intestinal epithelial barrier function
• Synergistic anti-inflammatory action when combined with other recovery peptides

Who it's for

• Gut inflammation — IBD adjunct, leaky gut, chronic GI inflammation
• Inflammatory skin conditions as part of a topical or systemic protocol
• Adjunct anti-inflammatory support within a BPC-157 / TB-500 recovery stack
• Chronic inflammatory conditions where cytokine load is a concern

• Pregnancy (insufficient data)
• Those with autoimmune conditions on immunosuppressive therapy — monitor carefully
• As a sole intervention for serious inflammatory disease — adjunct use only

Protocol guidance

Contraindications & cautions

• Human clinical trial data is limited — primarily preclinical and in vitro evidence
• Monitor for any paradoxical immune activation in autoimmune patients
• Well-tolerated in available studies; adverse effect profile appears minimal

Pairs well with

Research